Immupharma appoints Board Chairman Tim McCarthy as CEO and welcomes Dr. Sanjeev Pandya as Senior Independent Director and Lisa Baderoon as Non-Executive Director

– UK, London –  ImmuPharma PLC (LON: IMM | EBR: ALIMM), the specialist drug discovery and development company, today announced the appointment of its Board Chairman Tim McCarthy to the additional role of CEO following the resignation of current CEO Dimitri Dimitriou who has informed the Board that he wishes to step down from his position, to pursue several other external opportunities.

The Company has initiated a process to identify a suitable person to take over as Non-Executive Chair.

Further, Dr. Franco di Muzio, Senior Non-Executive Director, and Dr. Stéphane Méry have also decided that now is an appropriate time for each of them to step down from the Board.

Concurrently, the company announced the appointments to its Board of Dr. Sanjeev Pandya as Senior Independent Non-Executive Director and Lisa Baderoon as a Non-Executive Director with immediate effect.

I am delighted to welcome Sanjeev to the Board. Sanjeev’s experience, in both operational scaling of drug development businesses and his direct experience of engaging with investors both in the UK and internationally, will provide us with the appropriate skills and knowledge that we require for the next stage of our journey with ImmuPharma and he will be an excellent complement to Dr Tim Franklin, COO, who was recently appointed to the Board. I am also extremely pleased to welcome Lisa to the Board. Having worked with Lisa over a number of years, I have been continually impressed by her leadership skills and work ethic. Lisa has an intimate knowledge of how ImmuPharma operates and is integral to shareholder communication and representation and she will contribute an enormous amount to the quality of the Board.” said CEO Tim McCarthy.

About Dr Sanjeev Pandya

Sanjeev has over 25 years of healthcare and international management experience. Sanjeev was formerly CEO of Advanced Oncotherapy Plc, a specialist cancer radiotherapy business listed on AIM. During his leadership, Sanjeev raised over $100m and developed and secured partnerships in the USA, EU, China, Singapore, India, Australia, Asia, and South America. Formerly, Sanjeev had several leadership roles in several global clinical trials at Pfizer and was head of Europe Regulatory and Medical at Reckitt Benckiser. The experience Sanjeev brings in growing drug development businesses and mentoring commercial and clinical teams will be hugely invaluable to ImmuPharma, as we move through our next phase of development.

About Lisa Baderoon

Lisa Baderoon has been advising ImmuPharma since its flotation on AIM in 2006 and was appointed Head of Investor Relations in 2012. Lisa’s key activities over the last period have been in providing strategic advice to the Board and liaising with investors, stakeholders, and advisors of the Company. On joining the Board Lisa will be ensuring that shareholders’ views and interests continue to be fully represented. Formerly, Lisa was a longstanding Partner at London-based Buchanan Communications, one of the leading Financial PR agencies and part of WPP plc, heading up the Healthcare division. Lisa is also the founder of Just B Communications Ltd, a bespoke advisory consultancy to both private and public companies.

About ImmuPharma PLC

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives, and cancer. The lead program, Lupuzor, is a first-in-class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest a therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive license and development agreement and trademark agreement for Lupuzor to fund a new international Phase 3 trial for Lupuzor and commercialize in the US.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.